Comprehensive geriatric assessment was shown to effectively identify vulnerability to AEs in patients with HNC across all ages.
In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.
Patients with OPC with HPV-negative tumors have increased risk for head and neck cancer mortality.
HPV-positive sinonasal squamous cell carcinoma associated with improved overall survival.
Overall, 87.4 percent of 239 patients achieved negative margins with endoscopic resection.
Significant slowing found in rate of increase from 2009 to 2014, followed by stable rate since 2014.
[OncoTargets and Therapy] Researchers outline the case of a 93-year-old female with advanced ATC who received initial treatment with apatinib.
This review seeks to shed light on a relatively common but poorly understood adverse effect of radiotherapy for primary and metastatic brain or head and neck tumors.
Authors recommend pembrolizumab, with or without chemotherapy, as first-line treatment.